Agenus Inc (NASDAQ:AGEN) Announces Participation In Three Oncology Conferences

Agenus Inc (NASDAQ:AGEN) Announces Participation In Three Oncology Conferences

Agenus Inc (NASDAQ:AGEN) an immuno-oncology organization creating checkpoint modulator antibodies as well as cancer vaccines declared participation in The Sixth Annual William Blair and Maidstone Life Sciences conference in New York at the Apella Event Space Alexandria Center on March 31. President of R&D Robert B. Stein will helm 3 panels and speak at the conference.

Click Here For More Market Exclusive Updates & Analysis

The company will also participate in other conferences as follows:

Cancer Advance Boston at Harvard Medical School in Boston at Joseph B. Martin Conference Center on April 4. Dr. Stein will helm a panel at 4:10 pm termed “Combination Therapy.”

Jefferies Immuno-Oncology Summit it Boston at the Boston Harbor Hotel on April 7. Dr. Stein will speak at 1:45 pm.

On March 3rd, Agenus gave a corporate update and reported financial data for the fourth quarter and year ended December 31.

Agenus concentrates on the detection as well as development of novel treatments that harness the body’s immune system primarily to help cancer patients.

Chairman and CEO of Agenus, Dr. Garo H. Armen said that in 2015 the company expanded its capabilities and made progress in its portfolio of checkpoint antibodies as well as varied vaccine platforms. The organization made a number of strategic acquisitions in its bid to accelerate development and discovery and also to enhance the quality of its leads and programs. The company validated its portfolio as well as detection capabilities via strategic pacts with Merck and Co. Inc. (NYSE:MRK) and Incyte Corporation (NASDAQ:INCY).

Agenus is adopting a multidisciplinary approach that will depend on the capability to pinpoint subpopulations of patients that are probable best responders to particular immuno-oncology (I/O) agents or combinations. That is why Agenus is aiming at a combination of cell therapies, antibodies, vaccines as well as adjuvants.

To support all these efforts, in 2015 the company bolstered its cash position via partnerships, a non-dilutive royalty funding and a stock offering supporting the company through the initial half of 2017.